Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.51 -0.27 (-0.42%)
Streaming Delayed Price Updated: 11:56 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,738,057
Open 64.78
Bid (Size) 64.50 (7)
Ask (Size) 64.52 (4)
Prev. Close 64.78
Today's Range 64.34 - 65.12
52wk Range 64.33 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace

Performance

YTD
-22.50%
-22.50%
1 Month
-7.29%
-7.29%
3 Month
-15.90%
-15.90%
6 Month
-20.50%
-20.50%
1 Year
-17.92%
-17.92%

More News

Read More
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Sciences Unusual Options Activity
Via Benzinga
3 Dividend Stocks to Buy at a 52-Week Low in April
Via InvestorPlace
Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?
Via Investor's Business Daily
Exposures COVID-19
The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts
Via Benzinga
What the Options Market Tells Us About Gilead Sciences
Via Benzinga
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Gilead Sciences Announces First Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
Via Benzinga
Why the dividend investor may take a look at NASDAQ:GILD.
Via Chartmill
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Via Benzinga
Exposures Product Safety
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Via Benzinga
Undervalued Icons: 3 Household Names Trading at Steep Discounts
Via InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Via The Motley Fool
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.